<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105347</url>
  </required_header>
  <id_info>
    <org_study_id>42-ZS-2925</org_study_id>
    <nct_id>NCT05105347</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis</brief_title>
  <official_title>Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis, Compared With Adalimumab Plus High Dose Oral Glucocorticosteroid, a Non-inferior, Multi-center, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center randomized non-inferiority study that aims to observe the&#xD;
      short-term (3 months) efficacy and safety of adalimumab plus medium-dose glucocorticosteroid&#xD;
      (30mg/d prednisone or equivalent) with slow tapering for recurrent Behçet's uveitis (BU)&#xD;
      attack compared with adalimumab plus high-dose glucocorticosteroid (60mg/d prednisone or&#xD;
      equivalent) with slow tapering.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the most recent European League Against Rheumatism (EULAR) recommendation,&#xD;
      patients presenting with an initial or recurrent episode of acute sight-threatening uveitis&#xD;
      should be treated with high-dose glucocorticoids, infliximab or interferon-α. Adalimumab,&#xD;
      another TNFα antagonist, is also considered as an alternative for infliximab and have proved&#xD;
      its efficacy in several RCTs in the treatment of non-infectious intermediate, posterior and&#xD;
      pan-uveitis. As higher dose glucocorticosteroid have greater side effects, this study aims to&#xD;
      evaluate the non-inferior efficacy and safety of adalimumab plus medium-dose&#xD;
      glucocorticosteroid compared with adalimumab plus high-dose glucocorticosteroid (and slow&#xD;
      tapering) for recurrent posterior or pan-uveitis attack of Behcet's uveitis. Refractory BU is&#xD;
      defined as relapse of posterior or panuveitis with at least 10mg daily prednisone (or&#xD;
      equivalent). The acute attack will be controlled with adalimumab (80mg once, 40mg q2w&#xD;
      thereafter) plus medium dose initial oral glucocorticosteroid (30mg daily prednisone or&#xD;
      equivalent) in the &quot;medium dose&quot; group or plus high dose oral glucocorticosteroid (60mg daily&#xD;
      prednisone or equivalent) in the &quot;high dose&quot; group with fixed tapering protocols. Patients&#xD;
      will be followed up at 2w, 4w, 8w, and 12w after initiation of treatment. The primary&#xD;
      endpoint is the inflammatory control rate. Secondary endpoints are BCVA, vascular leakage&#xD;
      score on fundus fluorescein angiography (FFA), BOS 24 score and uveitis deterioration rate.&#xD;
      The safety profiles of both groups will be also monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uveitis control</measure>
    <time_frame>3 months</time_frame>
    <description>Inflammation control according to SUN criteria (two steps decrease of anterior chamber cell or vitreous haze or decreased to zero) or active retinal lesion recession with vitreous haze less than 0.5 grade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>3 months</time_frame>
    <description>BCVA was transformed into logMar form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of vascular leakage</measure>
    <time_frame>3 months</time_frame>
    <description>Vascular leakage was quantified based on the method developed by the Angiography Scoring for Uveitis Working Group (ASUWOG), in which vascular leakage in the posterior pole and in each peripheral quadrant was scored 1 if limited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOS 24 score</measure>
    <time_frame>3 months</time_frame>
    <description>BOS 24 scoring system refers to article &quot;Behc et's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uveitis deterioration</measure>
    <time_frame>3 months</time_frame>
    <description>Inflammation deterioration according to SUN criteria (two steps increase of anterior chamber cell or vitreous haze or increases to grade 4) or new active retinal lesions or new onset of retinal vasculitis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Medium dose group (Adalimumab plus medium dose oral glucocorticosteroid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given adalimumab with 30mg daily prednisone or equivalent with a fixed slow tapering plan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group (Adalimumab plus high dose oral glucocorticosteroid)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given adalimumab with 60mg daily prednisone or equivalent with a fixed slow tapering plan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab plus different doses of oral glucocorticosteroid</intervention_name>
    <description>A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.</description>
    <arm_group_label>High dose group (Adalimumab plus high dose oral glucocorticosteroid)</arm_group_label>
    <arm_group_label>Medium dose group (Adalimumab plus medium dose oral glucocorticosteroid)</arm_group_label>
    <other_name>Humira, prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Behçet's disease (BD) patients fulfilling the International Criteria for Behçet's&#xD;
             disease (ICBD) published in 2013 with recent recurrence of pan- or posterior uveitis&#xD;
&#xD;
          -  The patient should be on ≥10mg/d oral prednisone or equivalent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with TNFα inhibitors within 3 months&#xD;
&#xD;
          -  Pregnancy, breast feeding women&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Demyelinating diseases&#xD;
&#xD;
          -  Renal impairment (creatinine &gt; 1.5 mg/dl)&#xD;
&#xD;
          -  Depression or other psychic disorders&#xD;
&#xD;
          -  History of acute or chronic inflammatory joint or autoimmune disease&#xD;
&#xD;
          -  Patients with severe extra-ocular involvement other than oral/genital ulcer and skin&#xD;
             involvement&#xD;
&#xD;
          -  Organ or bone marrow transplant recipient, cardiac failure &gt; NYHA III&#xD;
&#xD;
          -  Acute liver disease with ALT or SGPT 2x above normal&#xD;
&#xD;
          -  White blood cell count &lt; 3500/mm^3&#xD;
&#xD;
          -  Platelet count &lt; 100000/mm^3&#xD;
&#xD;
          -  Hgb &lt; 8.5g/dl&#xD;
&#xD;
          -  T-SPOT TB: ≥200 SFCs per 10^6 PBMC&#xD;
&#xD;
          -  Active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or&#xD;
             other contraindications of intermediate dose corticosteroids&#xD;
&#xD;
          -  Other severe ocular diseases or intraocular surgery within 3 months&#xD;
&#xD;
          -  Media opacity precluding a clear view of the fundus&#xD;
&#xD;
          -  Positive screen test for HBV, HCV, HIV infection or syphilis&#xD;
&#xD;
          -  Body weight &lt;45 kg&#xD;
&#xD;
          -  Alcohol abuse or drug abuse&#xD;
&#xD;
          -  Mental impairment&#xD;
&#xD;
          -  Uncooperative attitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hang Song, MD</last_name>
    <phone>+8615600612346</phone>
    <email>songhang_pumch@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chan Zhao, MD</last_name>
    <phone>+8613810454083</phone>
    <email>zhaochan@pumch.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.</citation>
    <PMID>27602665</PMID>
  </reference>
  <reference>
    <citation>Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.</citation>
    <PMID>24359625</PMID>
  </reference>
  <reference>
    <citation>Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D; French Behçet Network. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015 Aug;62:67-74. doi: 10.1016/j.jaut.2015.06.005. Epub 2015 Jul 8.</citation>
    <PMID>26162757</PMID>
  </reference>
  <reference>
    <citation>Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Kamoi K, Nakai K, Mizuki N, Ohguro N; Ocular Behçet Disease Research Group of Japan. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014 Mar;58(2):120-30. doi: 10.1007/s10384-013-0294-0. Epub 2014 Jan 31.</citation>
    <PMID>24482146</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>email contact person if needed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

